Stephanie Berg, MD, Dana-Farber Cancer Institute, discusses the results of the of the PEACE-1 and ARASENS trials. In the phase 3 PEACE-1 trial, adding abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved overall survival (OS) and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. In the phase 3 ARASENS trial, adding darolutamide to standard ADT and docetaxel boosted OS versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.